SURMOUNT-2 Trial: Tirzepatide Results in Type 2 Diabetes and What the Full SURMOUNT Program Tells You

What Was SURMOUNT-2 and Why Does It Matter?

SURMOUNT-2 was a Phase 3, randomized, double-blind, placebo-controlled trial that specifically enrolled 938 adults with both obesity or overweight and type 2 diabetes. At 72 weeks, tirzepatide 15 mg produced 15.7% mean weight loss compared with 3.3% on placebo, and tirzepatide 10 mg produced 13.4% loss. That gap is clinically meaningful because type 2 diabetes consistently blunts pharmacologic weight loss responses relative to non-diabetic populations.

The trial was published in The Lancet in 2023 [1] and answered a precise question: could tirzepatide's dual mechanism, activating both GIP and GLP-1 receptors simultaneously, overcome the weight-loss attenuation that diabetes medications, insulin resistance, and beta-cell dysfunction typically impose? The data say yes. Participants who received tirzepatide 15 mg lost an average of 13.9 kg from baseline. Roughly 42% of those patients achieved at least 15% body weight reduction, versus fewer than 3% of placebo recipients.

HbA1c fell by 2.1 percentage points in the 15 mg group. That dual cardiometabolic benefit, substantial weight loss plus glycemic control, separates SURMOUNT-2 from older weight-loss drug trials where glucose outcomes were an afterthought.

How SURMOUNT-2 Compares Across the Full SURMOUNT Program

The SURMOUNT program comprises four completed Phase 3 trials. Putting them side by side clarifies what different patient populations can expect.

SURMOUNT-1 enrolled 2,539 adults without diabetes and BMI 30+ (or BMI 27+ with at least one weight-related comorbidity). At 72 weeks, tirzepatide 15 mg produced 22.5% mean weight loss versus 2.4% placebo [2]. That 22.5% figure is the highest ever reported for a pharmacologic agent in a key registration trial. Roughly one-third of participants on 15 mg lost at least 25% of body weight.

SURMOUNT-3 (N=579) took a different design angle: all participants completed an intensive 12-week lifestyle run-in before randomization, achieving about 6.9% weight loss before tirzepatide even started. From that lower baseline, tirzepatide 15 mg added another 18.4% loss over 72 weeks, yielding a total mean reduction of approximately 24.5% from original body weight [3]. This trial is relevant for patients who have already attempted lifestyle modification.

SURMOUNT-4 addressed the question every prescribing clinician eventually faces: what happens when tirzepatide is stopped? After a 36-week open-label lead-in (all participants on tirzepatide 10 or 15 mg), participants were randomized to continue tirzepatide or switch to placebo for another 52 weeks. Those who continued tirzepatide lost an additional 5.5%, while those switched to placebo regained 14.8% [4]. Discontinuation erased most of the benefit within one year.

Taken together, the SURMOUNT program describes a consistent dose-response curve, a diabetes-related attenuation of about 6 to 7 percentage points in peak weight loss, and a clear maintenance requirement.

The STEP Trials: Semaglutide's Evidence Base for Direct Comparison

Understanding SURMOUNT-2 in isolation misses half the clinical picture. The STEP program (four key trials plus extensions) established semaglutide 2.4 mg subcutaneous (Wegovy) as the prior benchmark. Here is what each STEP trial showed and why each one is still referenced by clinicians deciding between agents.

STEP-1: The Non-Diabetic Baseline

STEP-1 enrolled 1,961 adults with BMI 30+ or BMI 27+ with at least one comorbidity, excluding type 2 diabetes. At 68 weeks, semaglutide 2.4 mg produced 14.9% mean weight loss versus 2.4% placebo [5]. Approximately 86% of semaglutide participants achieved at least 5% loss; 69% achieved 10% or more. The trial was published in the New England Journal of Medicine in 2021 and served as the primary basis for the FDA's approval of Wegovy for chronic weight management [6].

The STEP-1 number, 14.9%, is the correct comparator when reading SURMOUNT-1's 22.5%. Both used non-diabetic populations. The 7.6-percentage-point advantage for tirzepatide's top dose likely reflects the additive GIP receptor activity.

STEP-2: Semaglutide in Type 2 Diabetes

STEP-2 is the direct analog to SURMOUNT-2 on the semaglutide side. It enrolled 1,210 adults with type 2 diabetes and BMI 27+. Semaglutide 1.0 mg (the dose approved for diabetes under the brand Ozempic) produced 9.6% weight loss at 68 weeks versus 3.4% placebo; semaglutide 2.4 mg produced 9.6% as well, roughly equivalent at the higher dose [7]. HbA1c fell 1.6 percentage points on semaglutide 2.4 mg.

Placing these numbers next to SURMOUNT-2's 15.7% (tirzepatide 15 mg in T2D), tirzepatide produced about 6 percentage points more weight loss in a comparable diabetic population. That difference may matter clinically when a patient needs both significant weight reduction and glycemic improvement.

STEP-3: Intensive Behavioral Therapy as an Add-On

STEP-3 asked whether combining semaglutide 2.4 mg with intensive behavioral therapy (IBT, 30 counseling sessions over 68 weeks) would outperform semaglutide alone. The trial enrolled 611 adults without diabetes. Semaglutide plus IBT produced 16.0% weight loss versus 5.7% with placebo plus IBT [8]. Semaglutide accounted for most of that effect. The behavioral arm added incremental benefit but did not double or triple the result.

The STEP-3 data are relevant for telehealth prescribers who pair medication with structured coaching. Adding rigorous lifestyle support to a GLP-1 agonist may add two to three percentage points over medication alone.

STEP-5: What Happens at Two Years?

STEP-5 followed 304 adults without diabetes on semaglutide 2.4 mg or placebo for 104 weeks, twice the duration of STEP-1. Mean weight loss was 15.2% in the semaglutide group versus 2.6% placebo at two years [9]. Weight loss trajectory showed a plateau around week 60 with modest regain after that, but the 15.2% at two years was not materially different from the 14.9% at 68 weeks in STEP-1.

The practical implication: for semaglutide, most achievable weight loss occurs within the first 60 to 68 weeks. Patients who plateau early are unlikely to see continued linear decline. Tirzepatide's SURMOUNT-3 data suggest a similar plateau profile, though the absolute endpoint is higher.

The SELECT Trial: Why Semaglutide's Cardiovascular Data Change the Prescribing Calculus

No obesity pharmacotherapy discussion is complete without SELECT, the largest cardiovascular outcomes trial ever run for an anti-obesity drug. SELECT enrolled 17,604 adults with overweight or obesity, pre-existing cardiovascular disease, and no diabetes. Semaglutide 2.4 mg reduced the rate of major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) by 20% versus placebo over a median 39.8 months (HR 0.80 to 95% CI 0.72 to 0.90, P<0.001) [10].

The SELECT editorial in NEJM 2023 stated: "The reduction in cardiovascular events occurred early and was maintained over the trial period, suggesting a mechanism that goes beyond weight loss alone." That mechanism likely involves direct GLP-1 receptor signaling in cardiac and vascular tissue.

There is no completed SURMOUNT equivalent for cardiovascular outcomes. The SURPASS-CVOT trial for tirzepatide in type 2 diabetes is ongoing as of early 2025. Clinicians choosing between tirzepatide and semaglutide for a patient with established cardiovascular disease should note this asymmetry: SELECT provides definitive mortality-adjacent data for semaglutide that tirzepatide does not yet have.

Head-to-Head: STEP-8 and Indirect Comparison Data

STEP-8 (N=338, published JAMA 2022) directly compared semaglutide 2.4 mg to liraglutide 3.0 mg in adults without diabetes over 68 weeks. Semaglutide produced 15.8% weight loss versus 6.4% with liraglutide [11]. Liraglutide's inferior efficacy largely removed it from first-line obesity pharmacotherapy in clinical practice guidelines.

There is no completed head-to-head RCT of tirzepatide versus semaglutide 2.4 mg in obesity. Indirect comparisons and network meta-analyses consistently favor tirzepatide on weight loss magnitude. One 2023 network meta-analysis published in Obesity Reviews estimated tirzepatide 15 mg produced approximately 6 to 8 percentage points more weight loss than semaglutide 2.4 mg in non-diabetic populations, though cross-trial comparisons carry methodological caveats about patient selection and trial duration.

Mechanism: Why Dual GIP/GLP-1 Agonism Outperforms GLP-1 Alone

Tirzepatide binds both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor with approximately equal affinity. GLP-1 receptor agonism suppresses appetite via hypothalamic pathways, slows gastric emptying, and stimulates insulin release in a glucose-dependent manner. GIP receptor agonism appears to act synergistically in adipose tissue, enhancing fat oxidation and reducing lipid accumulation through pathways distinct from GLP-1.

In rodent models, GIP receptor agonism alone had modest weight effects, but combined with GLP-1 agonism it produced greater caloric restriction than either alone. The SURMOUNT-1 data in humans confirm that this additive signal is clinically detectable: 22.5% at 72 weeks is roughly 7 to 8 percentage points beyond what semaglutide achieves in comparable populations.

Semaglutide (Wegovy) is a selective GLP-1 receptor agonist. Its Wegovy FDA-approved label [6] specifies use as an adjunct to reduced-calorie diet and increased physical activity for adults with BMI 30+ or BMI 27+ with at least one weight-related comorbidity. Tirzepatide's Zepbound label [12] mirrors that indication but carries the dual-agonist mechanism.

Dosing, Titration, and Tolerability Across Trials

Both agents use gradual titration to limit gastrointestinal adverse events. Tirzepatide starts at 2.5 mg weekly, increasing by 2.5 mg every four weeks to a target of 10 or 15 mg. Semaglutide 2.4 mg starts at 0.25 mg weekly, doubling approximately every four weeks to reach 2.4 mg over 16 to 20 weeks.

In SURMOUNT-2, the most common adverse events on tirzepatide were nausea (26.5% on 15 mg vs. 8.5% placebo), diarrhea (19.8% vs. 8.2%), and vomiting (14.0% vs. 3.2%) [1]. Serious adverse events occurred in 9.2% of the tirzepatide 15 mg group versus 7.1% placebo. Discontinuation due to adverse events was 8.5% on 15 mg, consistent with SURMOUNT-1 figures.

In STEP-1, nausea affected 44% of semaglutide participants versus 16% placebo. Vomiting occurred in 24% versus 6%. These rates appear higher than SURMOUNT-2 figures for tirzepatide, though cross-trial tolerability comparisons are not definitive given different populations, titration schedules, and reporting methods.

The AACE/ACE 2016 clinical practice guidelines state: "The goal of obesity pharmacotherapy is to improve the patient's health by reducing comorbidities and improving functional capacity, quality of life, and longevity, not simply to achieve a certain number on a scale" [13]. Both tirzepatide and semaglutide meet that standard based on available trial data.

Who Are the Ideal Candidates Based on Trial Data?

The SURMOUNT and STEP trials collectively define several patient archetypes where these agents have the strongest evidence base.

Adults with obesity (BMI 30+) and no diabetes are covered by STEP-1 and SURMOUNT-1. Tirzepatide offers higher absolute weight loss at maximum tolerated dose; semaglutide has a longer track record, a larger cardiovascular outcomes evidence base through SELECT, and established generic cost comparisons with older agents.

Adults with obesity and type 2 diabetes are covered by STEP-2 and SURMOUNT-2. Both agents improve HbA1c substantially. Tirzepatide's 15.7% weight loss versus semaglutide's 9.6% in comparable diabetic populations may favor tirzepatide for patients whose weight reduction target is aggressive, though glycemic equipoise is less clear given different doses and trial designs.

Adults who have already completed structured lifestyle intervention are covered by SURMOUNT-3, where tirzepatide added 18.4% from a post-lifestyle baseline. The STEP-3 data show a smaller but meaningful add-on for semaglutide in a similar scenario.

Adults concerned about long-term maintenance are informed by SURMOUNT-4 and STEP-5. Both datasets show that weight regain after discontinuation is substantial and rapid: 14.8% regained in one year after stopping tirzepatide (SURMOUNT-4), and roughly two-thirds of lost weight regained within one year after stopping semaglutide in STEP-1 extension analyses. Obesity is a chronic disease requiring chronic treatment.

Practical Prescribing Decisions at the Point of Care

A 52-year-old woman with BMI 34, type 2 diabetes (HbA1c 8.2%), and no prior GLP-1 use presents asking about "the Ozempic or the Mounjaro." Based on SURMOUNT-2 versus STEP-2 data, tirzepatide offers roughly 6 more percentage points of weight loss in that specific population. Her endocrinologist might reasonably start tirzepatide at 2.5 mg weekly, titrating every four weeks, targeting 10 to 15 mg by week 20. Monitoring should include HbA1c at 12 and 24 weeks, kidney function, and screening for personal or family history of medullary thyroid carcinoma (a contraindication listed in both labels).

A 61-year-old man with BMI 31, prior myocardial infarction two years ago, and no diabetes presents asking about weight-loss medication. SELECT's 20% MACE reduction is directly applicable. Semaglutide 2.4 mg has the only large-scale cardiovascular outcomes trial in this non-diabetic post-MI phenotype. The prescriber cannot reference an equivalent tirzepatide outcomes trial for this specific patient.

Insurance coverage, out-of-pocket cost, injection device preference, and supply availability remain real-world variables that trial data do not resolve.